Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods.

Leukemia

Corre J, Perrot A, Hulin C, Caillot D, Stoppa AM, Facon T, Leleu X, Dib M, Karlin L, Moreau P, Mohty M, Mariette C, Fontan J, Marolleau JP, Demarquette H, Slama B, Voillat L, Macro M, Orsini-Piocelle F, Brechignac S, Rey P, Collet P, Tiab M, Belhadj K, Lifermann F, Clement-Filliatre L, Sohn C, Richez V, Avet-Loiseau H.
PMID: 34099876
Leukemia. 2021 Dec;35(12):3600-3603. doi: 10.1038/s41375-021-01250-0. Epub 2021 Jun 07.

No abstract available.

Cite
Corre J, Perrot A, Hulin C, et al. Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. Leukemia. 2021;35(12):3600-3603doi: 10.1038/s41375-021-01250-0.
Corre, J., Perrot, A., Hulin, C., Caillot, D., Stoppa, A. M., Facon, T., Leleu, X., Dib, M., Karlin, L., Moreau, P., Mohty, M., Mariette, C., Fontan, J., Marolleau, J. P., Demarquette, H., Slama, B., Voillat, L., Macro, M., Orsini-Piocelle, F., Brechignac, S., Rey, P., Collet, P., Tiab, M., Belhadj, K., Lifermann, F., Clement-Filliatre, L., Sohn, C., Richez, V., Avet-Loiseau, H. (2021). Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. Leukemia, 35(12), 3600-3603. https://doi.org/10.1038/s41375-021-01250-0
Corre, Jill, et al. "Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods." Leukemia vol. 35,12 (2021): 3600-3603. doi: https://doi.org/10.1038/s41375-021-01250-0
Corre J, Perrot A, Hulin C, Caillot D, Stoppa AM, Facon T, Leleu X, Dib M, Karlin L, Moreau P, Mohty M, Mariette C, Fontan J, Marolleau JP, Demarquette H, Slama B, Voillat L, Macro M, Orsini-Piocelle F, Brechignac S, Rey P, Collet P, Tiab M, Belhadj K, Lifermann F, Clement-Filliatre L, Sohn C, Richez V, Avet-Loiseau H. Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. Leukemia. 2021 Dec;35(12):3600-3603. doi: 10.1038/s41375-021-01250-0. Epub 2021 Jun 07. PMID: 34099876.
Copy Download .nbib Format: NLM
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.

Blood

Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, Braun T, Adès L, Chantepie S, Lemasle E, Berthon C, Malfuson JV, Pautas C, Lambert J, Boissel N, Celli-Lebras K, Caillot D, Turlure P, Vey N, Pigneux A, Recher C, Terré C, Gardin C, Itzykson R, Preudhomme C, Dombret H, de Botton S.
PMID: 33881523
Blood. 2021 May 20;137(20):2827-2837. doi: 10.1182/blood.2020010165.

In patients with isocitrate dehydrogenase (IDH)-mutated acute myeloid leukemia (AML) treated by intensive chemotherapy (IC), prognostic significance of co-occurring genetic alterations and allogeneic hematopoietic stem cell transplantation (HSCT) are of particular interest with the advent of IDH1/2 mutant inhibitors....

Cite
Duchmann M, Micol JB, Duployez N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137(20):2827-2837doi: 10.1182/blood.2020010165.
Duchmann, M., Micol, J. B., Duployez, N., Raffoux, E., Thomas, X., Marolleau, J. P., Braun, T., Adès, L., Chantepie, S., Lemasle, E., Berthon, C., Malfuson, J. V., Pautas, C., Lambert, J., Boissel, N., Celli-Lebras, K., Caillot, D., Turlure, P., Vey, N., Pigneux, A., Recher, C., Terré, C., Gardin, C., Itzykson, R., Preudhomme, C., Dombret, H., & de Botton, S. (2021). Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood, 137(20), 2827-2837. https://doi.org/10.1182/blood.2020010165
Duchmann, Matthieu, et al. "Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study." Blood vol. 137,20 (2021): 2827-2837. doi: https://doi.org/10.1182/blood.2020010165
Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, Braun T, Adès L, Chantepie S, Lemasle E, Berthon C, Malfuson JV, Pautas C, Lambert J, Boissel N, Celli-Lebras K, Caillot D, Turlure P, Vey N, Pigneux A, Recher C, Terré C, Gardin C, Itzykson R, Preudhomme C, Dombret H, de Botton S. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021 May 20;137(20):2827-2837. doi: 10.1182/blood.2020010165. PMID: 33881523.
Copy Download .nbib Format: NLM
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.

Blood

Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B.
PMID: 34479366
Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285.

Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing

Cite
Caulier A, Roussel M, Morel P, et al. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021;138(25):2686-2695doi: 10.1182/blood.2021011285.
Caulier, A., Roussel, M., Morel, P., Lombion, N., Branco, B., Galtier, J., Hulin, C., Perrot, A., Richez, V., Michaud, A. V., Touzeau, C., Doyen, C., Mariette, C., Caillot, D., Harel, S., Lenain, P., Ivanoff, S., Fontan, J., Stoppa, A. M., Manier, S., Garderet, L., Leleu, X., Marolleau, J. P., Arnulf, B., Avet-Loiseau, H., & Royer, B. (2021). Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood, 138(25), 2686-2695. https://doi.org/10.1182/blood.2021011285
Caulier, Alexis, et al. "Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience." Blood vol. 138,25 (2021): 2686-2695. doi: https://doi.org/10.1182/blood.2021011285
Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285. PMID: 34479366.
Copy Download .nbib Format: NLM
Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.

Blood advances

Meliani A, Boisgerault F, Fitzpatrick Z, Marmier S, Leborgne C, Collaud F, Simon Sola M, Charles S, Ronzitti G, Vignaud A, van Wittenberghe L, Marolleau B, Jouen F, Tan S, Boyer O, Christophe O, Brisson AR, Maguire CA, Mingozzi F.
PMID: 29296848
Blood Adv. 2017 Oct 16;1(23):2019-2031. doi: 10.1182/bloodadvances.2017010181. eCollection 2017 Oct 24.

Results from clinical trials of liver gene transfer for hemophilia demonstrate the potential of the adeno-associated virus (AAV) vector platform. However, to achieve therapeutic transgene expression, in some cases high vector doses are required, which are associated with a...

Cite
Meliani A, Boisgerault F, Fitzpatrick Z, et al. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Adv. 2017;1(23):2019-2031doi: 10.1182/bloodadvances.2017010181.
Meliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., van Wittenberghe, L., Marolleau, B., Jouen, F., Tan, S., Boyer, O., Christophe, O., Brisson, A. R., Maguire, C. A., & Mingozzi, F. (2017). Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood advances, 1(23), 2019-2031. https://doi.org/10.1182/bloodadvances.2017010181
Meliani, Amine, et al. "Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors." Blood advances vol. 1,23 (2017): 2019-2031. doi: https://doi.org/10.1182/bloodadvances.2017010181
Meliani A, Boisgerault F, Fitzpatrick Z, Marmier S, Leborgne C, Collaud F, Simon Sola M, Charles S, Ronzitti G, Vignaud A, van Wittenberghe L, Marolleau B, Jouen F, Tan S, Boyer O, Christophe O, Brisson AR, Maguire CA, Mingozzi F. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Adv. 2017 Oct 16;1(23):2019-2031. doi: 10.1182/bloodadvances.2017010181. eCollection 2017 Oct 24. PMID: 29296848; PMCID: PMC5728288.
Copy Download .nbib Format: NLM
Determination of monochloramine dissipation kinetics in various surface water qualities under relevant environmental conditions - Consequences regarding environmental risk assessment.

The Science of the total environment

Sacher F, Gerstner P, Merklinger M, Thoma A, Kinani A, Roumiguières A, Bouchonnet S, Richard-Tanaka B, Layousse S, Ata R, Marolleau F, Kinani S.
PMID: 31181531
Sci Total Environ. 2019 Oct 01;685:542-554. doi: 10.1016/j.scitotenv.2019.05.364. Epub 2019 May 24.

A total 190 experiments were performed to study the dissipation kinetics of monochloramine (NH

Cite
Sacher F, Gerstner P, Merklinger M, et al. Determination of monochloramine dissipation kinetics in various surface water qualities under relevant environmental conditions - Consequences regarding environmental risk assessment. Sci Total Environ. 2019;685:542-554doi: 10.1016/j.scitotenv.2019.05.364.
Sacher, F., Gerstner, P., Merklinger, M., Thoma, A., Kinani, A., Roumiguières, A., Bouchonnet, S., Richard-Tanaka, B., Layousse, S., Ata, R., Marolleau, F., & Kinani, S. (2019). Determination of monochloramine dissipation kinetics in various surface water qualities under relevant environmental conditions - Consequences regarding environmental risk assessment. The Science of the total environment, 685542-554. https://doi.org/10.1016/j.scitotenv.2019.05.364
Sacher, Frank, et al. "Determination of monochloramine dissipation kinetics in various surface water qualities under relevant environmental conditions - Consequences regarding environmental risk assessment." The Science of the total environment vol. 685 (2019): 542-554. doi: https://doi.org/10.1016/j.scitotenv.2019.05.364
Sacher F, Gerstner P, Merklinger M, Thoma A, Kinani A, Roumiguières A, Bouchonnet S, Richard-Tanaka B, Layousse S, Ata R, Marolleau F, Kinani S. Determination of monochloramine dissipation kinetics in various surface water qualities under relevant environmental conditions - Consequences regarding environmental risk assessment. Sci Total Environ. 2019 Oct 01;685:542-554. doi: 10.1016/j.scitotenv.2019.05.364. Epub 2019 May 24. PMID: 31181531.
Copy Download .nbib Format: NLM
The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma.

Frontiers in immunology

Trudel S, Ghamlouch H, Dremaux J, Delette C, Harrivel V, Marolleau JP, Gubler B.
PMID: 28082975
Front Immunol. 2016 Dec 27;7:625. doi: 10.3389/fimmu.2016.00625. eCollection 2016.

Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are hematological disorders that occur at different stages of B-cell development. It has been shown that CLL B-cells can differentiate into plasma cells

Cite
Trudel S, Ghamlouch H, Dremaux J, et al. The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma. Front Immunol. 2016;7:625doi: 10.3389/fimmu.2016.00625.
Trudel, S., Ghamlouch, H., Dremaux, J., Delette, C., Harrivel, V., Marolleau, J. P., & Gubler, B. (2016). The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma. Frontiers in immunology, 7625. https://doi.org/10.3389/fimmu.2016.00625
Trudel, Stéphanie, et al. "The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma." Frontiers in immunology vol. 7 (2016): 625. doi: https://doi.org/10.3389/fimmu.2016.00625
Trudel S, Ghamlouch H, Dremaux J, Delette C, Harrivel V, Marolleau JP, Gubler B. The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma. Front Immunol. 2016 Dec 27;7:625. doi: 10.3389/fimmu.2016.00625. eCollection 2016. PMID: 28082975; PMCID: PMC5187371.
Copy Download .nbib Format: NLM
Human Muscle Progenitor Cells Displayed Immunosuppressive Effect through Galectin-1 and Semaphorin-3A.

Stem cells international

Lecourt S, Lepelletier Y, Vanneaux V, Jarray R, Domet T, Raynaud F, Hadj-Slimane R, Cras A, Hermine O, Marolleau JP, Larghero J.
PMID: 22606205
Stem Cells Int. 2012;2012:412610. doi: 10.1155/2012/412610. Epub 2012 Apr 23.

In human skeletal muscle, myoblasts represent the main population of myogenic progenitors. We previously showed that, beside their myogenic differentiation capacities, myoblasts also differentiate towards osteogenic and chondrogenic lineages, some properties generally considered being hallmarks of mesenchymal stem cells...

Cite
Lecourt S, Lepelletier Y, Vanneaux V, et al. Human Muscle Progenitor Cells Displayed Immunosuppressive Effect through Galectin-1 and Semaphorin-3A. Stem Cells Int. 2012;2012:412610doi: 10.1155/2012/412610.
Lecourt, S., Lepelletier, Y., Vanneaux, V., Jarray, R., Domet, T., Raynaud, F., Hadj-Slimane, R., Cras, A., Hermine, O., Marolleau, J. P., & Larghero, J. (2012). Human Muscle Progenitor Cells Displayed Immunosuppressive Effect through Galectin-1 and Semaphorin-3A. Stem cells international, 2012412610. https://doi.org/10.1155/2012/412610
Lecourt, Séverine, et al. "Human Muscle Progenitor Cells Displayed Immunosuppressive Effect through Galectin-1 and Semaphorin-3A." Stem cells international vol. 2012 (2012): 412610. doi: https://doi.org/10.1155/2012/412610
Lecourt S, Lepelletier Y, Vanneaux V, Jarray R, Domet T, Raynaud F, Hadj-Slimane R, Cras A, Hermine O, Marolleau JP, Larghero J. Human Muscle Progenitor Cells Displayed Immunosuppressive Effect through Galectin-1 and Semaphorin-3A. Stem Cells Int. 2012;2012:412610. doi: 10.1155/2012/412610. Epub 2012 Apr 23. PMID: 22606205; PMCID: PMC3347758.
Copy Download .nbib Format: NLM
Functional Validation of a New Alginate-based Hydrogel Scaffold Combined with Mesenchymal Stem Cells in a Rat Hard Palate Cleft Model.

Plastic and reconstructive surgery. Global open

Naudot M, Davrou J, Djebara AE, Barre A, Lavagen N, Lardière S, Azdad SZ, Zabijak L, Lack S, Devauchelle B, Marolleau JP, Le Ricousse S.
PMID: 32440413
Plast Reconstr Surg Glob Open. 2020 Apr 29;8(4):e2743. doi: 10.1097/GOX.0000000000002743. eCollection 2020 Apr.

BACKGROUND: One of the major difficulties in cleft palate repair is the requirement for several surgical procedures and autologous bone grafting to form a bony bridge across the cleft defect. Engineered tissue, composed of a biomaterial scaffold and multipotent...

Cite
Naudot M, Davrou J, Djebara AE, et al. Functional Validation of a New Alginate-based Hydrogel Scaffold Combined with Mesenchymal Stem Cells in a Rat Hard Palate Cleft Model. Plast Reconstr Surg Glob Open. 2020;8(4):e2743doi: 10.1097/GOX.0000000000002743.
Naudot, M., Davrou, J., Djebara, A. E., Barre, A., Lavagen, N., Lardière, S., Azdad, S. Z., Zabijak, L., Lack, S., Devauchelle, B., Marolleau, J. P., & Le Ricousse, S. (2020). Functional Validation of a New Alginate-based Hydrogel Scaffold Combined with Mesenchymal Stem Cells in a Rat Hard Palate Cleft Model. Plastic and reconstructive surgery. Global open, 8(4), e2743. https://doi.org/10.1097/GOX.0000000000002743
Naudot, Marie, et al. "Functional Validation of a New Alginate-based Hydrogel Scaffold Combined with Mesenchymal Stem Cells in a Rat Hard Palate Cleft Model." Plastic and reconstructive surgery. Global open vol. 8,4 (2020): e2743. doi: https://doi.org/10.1097/GOX.0000000000002743
Naudot M, Davrou J, Djebara AE, Barre A, Lavagen N, Lardière S, Azdad SZ, Zabijak L, Lack S, Devauchelle B, Marolleau JP, Le Ricousse S. Functional Validation of a New Alginate-based Hydrogel Scaffold Combined with Mesenchymal Stem Cells in a Rat Hard Palate Cleft Model. Plast Reconstr Surg Glob Open. 2020 Apr 29;8(4):e2743. doi: 10.1097/GOX.0000000000002743. eCollection 2020 Apr. PMID: 32440413; PMCID: PMC7209877.
Copy Download .nbib Format: NLM
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.

Blood

Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B.
PMID: 34479366
Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285.

Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing

Cite
Caulier A, Roussel M, Morel P, et al. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021;138(25):2686-2695doi: 10.1182/blood.2021011285.
Caulier, A., Roussel, M., Morel, P., Lombion, N., Branco, B., Galtier, J., Hulin, C., Perrot, A., Richez, V., Michaud, A. V., Touzeau, C., Doyen, C., Mariette, C., Caillot, D., Harel, S., Lenain, P., Ivanoff, S., Fontan, J., Stoppa, A. M., Manier, S., Garderet, L., Leleu, X., Marolleau, J. P., Arnulf, B., Avet-Loiseau, H., & Royer, B. (2021). Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood, 138(25), 2686-2695. https://doi.org/10.1182/blood.2021011285
Caulier, Alexis, et al. "Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience." Blood vol. 138,25 (2021): 2686-2695. doi: https://doi.org/10.1182/blood.2021011285
Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285. PMID: 34479366.
Copy Download .nbib Format: NLM
Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy.

Blood

Bachy E, Houot R, Feugier P, Bouabdallah K, Bouabdallah R, Nicolas-Virelizier E, Maerevoet MMF, Fruchart C, Snauwaert S, Le Gouill S, Marolleau JP, Molina L, Moluçon Chabrot C, Thieblemont C, Tilly H, Bijou F, Haioun C, Van Den Neste EW, Fabiani B, Meignan M, Cartron G, Salles GA, Casasnovas RO, Morschhauser F.
PMID: 34936697
Blood. 2021 Dec 22; doi: 10.1182/blood.2021013526. Epub 2021 Dec 22.

Obinutuzumab and lenalidomide (GALEN) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously-untreated patients with advanced follicular lymphoma (FL)....

Cite
Bachy E, Houot R, Feugier P, et al. Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy. Blood. 2021;doi: 10.1182/blood.2021013526.
Bachy, E., Houot, R., Feugier, P., Bouabdallah, K., Bouabdallah, R., Nicolas-Virelizier, E., Maerevoet, M. M. F., Fruchart, C., Snauwaert, S., Le Gouill, S., Marolleau, J. P., Molina, L., Moluçon Chabrot, C., Thieblemont, C., Tilly, H., Bijou, F., Haioun, C., Van Den Neste, E. W., Fabiani, B., Meignan, M., Cartron, G., Salles, G. A., Casasnovas, R. O., & Morschhauser, F. (2021). Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy. Blood, . https://doi.org/10.1182/blood.2021013526
Bachy, Emmanuel, et al. "Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2021013526
Bachy E, Houot R, Feugier P, Bouabdallah K, Bouabdallah R, Nicolas-Virelizier E, Maerevoet MMF, Fruchart C, Snauwaert S, Le Gouill S, Marolleau JP, Molina L, Moluçon Chabrot C, Thieblemont C, Tilly H, Bijou F, Haioun C, Van Den Neste EW, Fabiani B, Meignan M, Cartron G, Salles GA, Casasnovas RO, Morschhauser F. Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy. Blood. 2021 Dec 22; doi: 10.1182/blood.2021013526. Epub 2021 Dec 22. PMID: 34936697.
Copy Download .nbib Format: NLM
Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults.

HemaSphere

Fenwarth L, Caulier A, Lachaier E, Goursaud L, Marceau-Renaut A, Fournier E, Lebon D, Boyer T, Berthon C, Marolleau JP, Preudhomme C, Duployez N.
PMID: 33778416
Hemasphere. 2021 Mar 23;5(4):e552. doi: 10.1097/HS9.0000000000000552. eCollection 2021 Apr.

No abstract available.

Cite
Fenwarth L, Caulier A, Lachaier E, et al. Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults. Hemasphere. 2021;5(4):e552doi: 10.1097/HS9.0000000000000552.
Fenwarth, L., Caulier, A., Lachaier, E., Goursaud, L., Marceau-Renaut, A., Fournier, E., Lebon, D., Boyer, T., Berthon, C., Marolleau, J. P., Preudhomme, C., & Duployez, N. (2021). Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults. HemaSphere, 5(4), e552. https://doi.org/10.1097/HS9.0000000000000552
Fenwarth, Laurène, et al. "Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults." HemaSphere vol. 5,4 (2021): e552. doi: https://doi.org/10.1097/HS9.0000000000000552
Fenwarth L, Caulier A, Lachaier E, Goursaud L, Marceau-Renaut A, Fournier E, Lebon D, Boyer T, Berthon C, Marolleau JP, Preudhomme C, Duployez N. Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults. Hemasphere. 2021 Mar 23;5(4):e552. doi: 10.1097/HS9.0000000000000552. eCollection 2021 Apr. PMID: 33778416; PMCID: PMC7990008.
Copy Download .nbib Format: NLM
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.

European journal of haematology

Bouvier A, Hamel JF, Delaunay J, Delabesse E, Dumas PY, Ledoux MP, Peterlin P, Luquet I, Roth Guepin G, Bulabois CE, Gallego Hernanz MP, Guillerm G, Guieze R, Hicheri Y, Simand C, Himberlin C, Hunault-Berger M, Bernard M, Jourdan E, Caillot D, Dorvaux V, Tavernier E, Daguindau E, Banos A, Ojeda-Uribe M, Gyan E, Alexis M, Marolleau JP, Turlure P, Bouscary D, Humbrecht C, Zerazhi H, Béné MC, Pigneux A, Carre M, Ifrah N, Blanchet O, Vey N, Récher C, Cornillet-Lefèbvre P.
PMID: 33765335
Eur J Haematol. 2021 Jul;107(1):111-121. doi: 10.1111/ejh.13626. Epub 2021 Apr 18.

In this randomized phase 3 study, the FILO group tested whether the addition of 6 mg/m

Cite
Bouvier A, Hamel JF, Delaunay J, et al. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial. Eur J Haematol. 2021;107(1):111-121doi: 10.1111/ejh.13626.
Bouvier, A., Hamel, J. F., Delaunay, J., Delabesse, E., Dumas, P. Y., Ledoux, M. P., Peterlin, P., Luquet, I., Roth Guepin, G., Bulabois, C. E., Gallego Hernanz, M. P., Guillerm, G., Guieze, R., Hicheri, Y., Simand, C., Himberlin, C., Hunault-Berger, M., Bernard, M., Jourdan, E., Caillot, D., Dorvaux, V., Tavernier, E., Daguindau, E., Banos, A., Ojeda-Uribe, M., Gyan, E., Alexis, M., Marolleau, J. P., Turlure, P., Bouscary, D., Humbrecht, C., Zerazhi, H., Béné, M. C., Pigneux, A., Carre, M., Ifrah, N., Blanchet, O., Vey, N., Récher, C., Cornillet-Lefèbvre, P. (2021). Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial. European journal of haematology, 107(1), 111-121. https://doi.org/10.1111/ejh.13626
Bouvier, Anne, et al. "Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial." European journal of haematology vol. 107,1 (2021): 111-121. doi: https://doi.org/10.1111/ejh.13626
Bouvier A, Hamel JF, Delaunay J, Delabesse E, Dumas PY, Ledoux MP, Peterlin P, Luquet I, Roth Guepin G, Bulabois CE, Gallego Hernanz MP, Guillerm G, Guieze R, Hicheri Y, Simand C, Himberlin C, Hunault-Berger M, Bernard M, Jourdan E, Caillot D, Dorvaux V, Tavernier E, Daguindau E, Banos A, Ojeda-Uribe M, Gyan E, Alexis M, Marolleau JP, Turlure P, Bouscary D, Humbrecht C, Zerazhi H, Béné MC, Pigneux A, Carre M, Ifrah N, Blanchet O, Vey N, Récher C, Cornillet-Lefèbvre P. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial. Eur J Haematol. 2021 Jul;107(1):111-121. doi: 10.1111/ejh.13626. Epub 2021 Apr 18. PMID: 33765335.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries